Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Beneficial effects of probiotics have been reported in liver disease. Inflammatory bowel disease concurs in 90% of primary sclerosing cholangitis (PSC) patients, suggesting that substances originating from the inflamed gut may damage the biliary tree. OBJECTIVE: To assess potential beneficial effects of probiotics on serum liver tests, pruritus and fatigue in PSC. METHODS: Fourteen patients (13 male/one female, mean age 45 years), with concurrent inflammatory bowel disease were randomized to treatment with probiotics (Ecologic 641, containing four Lactobacillus and two Bifidobacillus strains; Winclove Bio Industries, Amsterdam, The Netherlands) or placebo during 3 months in a double-blind fashion. After a 1-month washout period, crossover was made. RESULTS: No changes in pruritus, fatigue and stool frequency were noted during placebo or probiotics. No significant differences were observed between treatment with probiotics and placebo in bilirubin (at end of probiotic vs. placebo period: -13 vs. -15% change from baseline; P=0.89), alkaline phosphatase (-9 vs. -9%; P=0.99), gamma glutamyl transpeptidase (-11 vs. -5%; P=0.60), aspartate aminotransferase (-16 vs. -15%; P=0.99), alanine aminotransferase (-27 vs. -26%; P=0.97), prothrombin, albumin or bile salts. CONCLUSION: Our data do not support beneficial effects of probiotics on symptoms, liver biochemistry or liver function in PSC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a small study (n = 14) with a probiotic containing Bifidobacillus and Lactobacillus showed no beneficial effects on liver biochemistries, including serum ALP, compared to placebo at the end of treatment over 3 months.212”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [212]
In the citing paper
“Probiotics have been rather disappointing in treatment of NASH60 and cholestatic disorders such as PSC,61”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [61]
Citations
Cites
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Rembacken, B., Snelling, A., Hawkey, P., Chalmers, D., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,101
Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
Liu, Q., Duan, Z. P., Ha, D. K., Bengmark, S., Kurtovic, J., & Riordan, S. M. (2004) · Hepatology · doi:10.1002/hep.20194 · Cited by 638
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Pardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
Alander, M., Satokari, R., Korpela, R., Saxelin, M., Vilpponen-Salmela, T., Mattila-Sandholm, T., & von Wright, A. (1999) · Applied and Environmental Microbiology · doi:10.1128/aem.65.1.351-354.1999 · Cited by 530
Primary Sclerosing Cholangitis
Lee, Y.-M., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 526
Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases
Loguercio, C., Federico, A., Tuccillo, C., Terracciano, F., D'Auria, M. V., De Simone, C., & Blanco, C. D. V. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000165671.25272.0f · Cited by 449
Primary sclerosing cholangitis
Lawson, A. (2014) · Radiopaedia.org · doi:10.53347/rid-26818 · Cited by 443
Cited by
Targeting the gut-liver axis in liver disease
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S., & Jalan, R. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.007 · Cited by 419
Saez-Lara, M. J., Gomez-Llorente, C., Plaza-Diaz, J., & Gil, A. (2015) · BioMed Research International · doi:10.1155/2015/505878 · Cited by 388
“The absence of any significant positive effects was attributed to the concurrent use of UCDA, the relatively small number of patients studied, or the relatively short duration of treatment [87].”
BackgroundEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247
Effects of dietary components on intestinal permeability in health and disease
Khoshbin, K., & Camilleri, M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00245.2020 · Cited by 195
Metadata
- Authors
- Vleggaar, F. P., Monkelbaan, J. F., & van Erpecum, K. J.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Vleggaar, Frank P.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2008-07
- Volume
- 20
- Issue
- 7
- Pages
- 688-692
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2062111585
- Cited by
- 110
- References
- 20
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 9 · 2021: 10 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 2 · 2015: 9 · 2014: 6 · 2013: 3 · 2012: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- probiotics, primary sclerosing cholangitis, inflammatory bowel disease, Lactobacillus, Bifidobacterium, liver function tests, pruritus, fatigue, bile acid metabolism, gut-liver axis
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bifidobacterium, Bilirubin, Epidemiologic Methods, Fatigue, Female, Humans, Lactobacillus, Liver, Male, Middle Aged, Pruritus, Cholangitis, Sclerosing, Biomarkers, Treatment Outcome, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. https://app.cochat.ai/papers/10.1097/meg.0b013e3282f5197e
- The paper
- Vleggaar, F. P., Monkelbaan, J. F., & van Erpecum, K. J. (2008). Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/meg.0b013e3282f5197e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.